ILMN — Illumina, Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Company profile
- Sector: Healthcare
- Industry: Medical - Diagnostics & Research
- Country: US
- Exchange: NASDAQ
- Employees: 8,970
- Website: https://www.illumina.com
Latest SEC filings for ILMN
- SCHEDULE 13G — 2026-10-07
- 8-K — 2026-08-17
- 8-K — 2026-08-13
- 8-K — 2026-08-12
- 424B2 — 2026-08-12
- FWP — 2026-08-10
- 424B2 — 2026-08-10
- 8-K — 2026-08-07
- 10-Q — 2026-07-31
- 8-K — 2026-07-30
Latest ILMN news
- — Illumina (ILMN) Reports Next Week: Wall Street Expects Earnings Growth (Zacks Investment Research)
- — How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks Investment Research)
- — Single Cell Sequencing Market Forecast to 2035: Services, Technologies, End-users, Applications, and Regions | 15% CAGR Drives Drug Discovery and Precision Medicine Growth (GlobeNewswire Inc.)
- — Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? (Zacks Investment Research)
- — Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million (GlobeNewswire Inc.)
- — Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? (Zacks Investment Research)
- — Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs (prnewswire.com)
- — Should Invesco S&P MidCap Quality ETF (XMHQ) Be on Your Investing Radar? (Zacks Investment Research)
- — Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026 (prnewswire.com)
- — Illumina releases SpliceAI2 to help advance rare disease research (prnewswire.com)
Educational tool only — not investment advice.